Indoco Remedies Ltd. (INDOCO) — Tipsheet

Indoco cuts debt target, USFDA audit still open

Tipsheet Editorial — Tue, 28 Jul 2026 16:44:24 GMT

Q1 EBITDA margin improved to 10.3% from 3.8%, but management lowered near-term debt repayment goal by ₹30 crore and gave no timeline for USFDA clearance.

What’s new

Management lowered near-term debt repayment target to ₹110 cr from ₹140 cr.
USFDA audit of Goa sterile plant remains unresolved with no timeline.
Standalone revenue grew 6% YoY to ₹408 cr; EBITDA margin improved to 10.3%.

Why it matters

The margin recovery shows operational improvement, but the debt pile of ~₹960 cr and ₹100 cr annual interest costs mean cash flow is still under pressure. The unresolved USFDA issue delays new US product approvals, capping growth.

What we’re watching

Timeline for USFDA resolution and new product approvals.
Debt reduction progress against revised ₹260 cr target over 17-18 months.
Sustainability of margin improvement beyond the exceptional gain from ophthalmic sale.

The full read

Indoco's Q1 showed operational improvement: EBITDA margins improved to 10.3% on 6% revenue growth. But the balance sheet and regulatory overhangs remain. Management cut its current-year debt repayment target by ₹30 crore to ₹110 crore and now guides for ₹260 crore total repayments over the next 17-18 months. That is a slowdown from the earlier pace. Meanwhile, the USFDA audit of the Goa sterile plant is still open with no end in sight, stalling US launches. The ₹97 crore exceptional gain from the ophthalmology division sale added some cash, but with consolidated debt of ~₹960 crore and annual interest near ₹100 crore, the relief is temporary. The open question is whether the margin recovery is sustainable without the one-off gain and with US headwinds.

Primary source: BSE · NSE

Indoco's ₹97 cr sale masks core loss; auditor flags subsidiary's future

Tipsheet Editorial — Tue, 28 Jul 2026 12:56:57 GMT

June-quarter profit of ₹65 cr is entirely from the ophthalmic division sale. Excluding it, operations are in the red. Auditor material uncertainty on FPP Holding adds another concern.

What’s new

Reported profit of ₹65 cr includes ₹97 cr one-time gain; underlying operations loss-making.
EBITDA margin at 10.3% with tight liquidity and consolidated debt of ₹960 cr.
Auditor flags FPP Holding's negative net worth of ₹38 cr as going concern uncertainty.

Why it matters

The headline profit is an optical lift from asset sale. Core business is struggling with debt at ₹960 cr and muted growth. The auditor's warning on a subsidiary adds governance risk.

What we’re watching

Ability to service debt from operations.
Any recovery in core margins.
Management's plan for FPP Holding.

The full read

Indoco reported ₹65 cr profit for June. That comes entirely from the ophthalmic sale — core operations are in the red. EBITDA margin is just 10.3%, and consolidated debt stands at ₹960 cr, nearly half the company's market capitalisation of ₹2,138 cr. The auditor's review flags FPP Holding's negative net worth of ₹38 cr as a material going concern uncertainty. A red flag. The ophthalmic sale provides cash, but the core business needs to generate profits to service that debt.

Primary source: BSE · NSE

Indoco Q1 profit hinges on ₹97 cr ophthalmic sale gain

Tipsheet Editorial — Tue, 28 Jul 2026 12:01:36 GMT

Standalone revenue up 6% to ₹408 cr, but pre-tax loss of ₹4.1 cr before exceptional items. EBITDA margin improves to 10.3% but core business under pressure.

What’s new

Standalone revenue up 6% YoY to ₹408 cr, but pre-tax loss of ₹4.1 cr before exceptional items.
Net profit of ₹82.3 cr entirely from one-time gain of ₹97.3 cr from ophthalmic sale.
EBITDA margin at 10.3% improved from 3.8% last year but down from 14.7% in Q4.

Why it matters

The profit is non-recurring; without the sale gain, the core business would have reported a loss. Investors should focus on underlying operational trends, not the headline number.

What we’re watching

Revenue growth trajectory in domestic vs international segments.
Margin trends without one-time gains – can EBITDA sustain above 10%?
Any new strategic initiatives post-ophthalmic sale.

The full read

Indoco's ₹82.3 cr standalone profit is a mirage. Strip out the ₹97.34 cr exceptional gain from selling its ophthalmic unit to Sunways India and the business actually lost ₹4.12 cr before tax. Revenue grew 6% to ₹408 cr — international led the way, up 11% to ₹180 cr, while domestic sales crawled 2% higher. EBITDA margin of 10.3% is better than the 3.8% last year, but well off the 14.7% of the March quarter. The sale is done; the cash is in. Now the company must prove it can generate sustainable profits from the remaining business. This quarter suggests that work is still underway.

Primary source: BSE · NSE